Pliant Therapeutics (PLRX) Accumulated Expenses (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Accumulated Expenses of $4.1 million for Q1 2026, down 44.23% year-over-year from $7.4 million in Q1 2025, and down 57.0% quarter-over-quarter from $9.6 million in Q4 2025.
Pliant Therapeutics (PLRX) Accumulated Expenses (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Accumulated Expenses for 8 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 44.23% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 44.23% YoY), while the FY2025 annual figure was $9.6 million, down 22.01% from the prior year.
- Accumulated Expenses retreated to $4.1 million in Q1 2026 per PLRX's latest filing, from $9.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $20.3 million in Q3 2022 and bottomed at $4.1 million in Q1 2026.
- Historically, Accumulated Expenses has averaged $9.5 million across 5 years, with a median of $8.3 million in 2023.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 112.97% — and 2023, when it tumbled 61.13%.
- Pliant Therapeutics' Accumulated Expenses stood at $8.7 million in 2022, then gained by 18.03% to $10.2 million in 2023, then grew by 20.88% to $12.4 million in 2024, then dropped by 22.01% to $9.6 million in 2025, then slumped by 57.0% to $4.1 million in 2026.
- Business Quant data shows PLRX's Accumulated Expenses at $4.1 million in Q1 2026, $9.6 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.65 Mn |
| Mar 31, 2026 | 4.14 Mn |
| Dec 31, 2025 | 9.63 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | 7.19 Mn |
| Mar 31, 2025 | 7.43 Mn |
| Dec 31, 2024 | 12.35 Mn |
| Sep 30, 2024 | 9.72 Mn |
| Jun 30, 2024 | 8.20 Mn |
| Mar 31, 2024 | 5.87 Mn |
| Dec 31, 2023 | 10.22 Mn |
| Sep 30, 2023 | 8.31 Mn |
| Jun 30, 2023 | 6.76 Mn |
| Mar 31, 2023 | 4.73 Mn |
| Dec 31, 2022 | 8.66 Mn |
| Sep 30, 2022 | 20.31 Mn |
| Jun 30, 2022 | 17.40 Mn |
| Mar 31, 2022 | 11.63 Mn |
| Dec 31, 2021 | 6.12 Mn |
| Sep 30, 2021 | 10.32 Mn |